Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
Ravindra Pramod Deshpande, Sambad Sharma, Kounosuke Watabe
Cancers (2020) Vol. 12, Iss. 10, pp. 2983-2983
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
Leisha A. Emens, Pedro Romero, Ana C. Anderson, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009063-e009063
Open Access | Times Cited: 25
Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
Lindsey Carlsen, Kelsey E. Huntington, Wafik S. El‐Deiry
Cancers (2022) Vol. 14, Iss. 4, pp. 1028-1028
Open Access | Times Cited: 41
Immune Checkpoint Inhibitors—Associated Cardiotoxicity
Chenghui Li, Sajjad Bhatti, Jun Ying
Cancers (2022) Vol. 14, Iss. 5, pp. 1145-1145
Open Access | Times Cited: 39
Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature
Jing He, Ziwei Chen, Qingfeng Xue, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 38
The role of mitochondria in the resistance of melanoma to PD-1 inhibitors
Fei Du, Lu-han Yang, Jiao Liu, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 22
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
Nicolas D. Huyghe, Elena Benidovskaya, Philippe Stevens, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2241-2241
Open Access | Times Cited: 37
How Did Conventional Nanoparticle-Mediated Photothermal Therapy Become “Hot” in Combination with Cancer Immunotherapy?
Wan Su Yun, Ji‐Ho Park, Dong‐Kwon Lim, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 2044-2044
Open Access | Times Cited: 35
Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
Rita Balsano, Valentina Zanuso, Angelo Pirozzi, et al.
Current Oncology (2023) Vol. 30, Iss. 4, pp. 3871-3885
Open Access | Times Cited: 18
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Kuba Retecki, Milena Seweryn, Agnieszka Graczyk‐Jarzynka, et al.
Cancers (2021) Vol. 13, Iss. 23, pp. 6012-6012
Open Access | Times Cited: 39
New Therapeutic Strategies for Adult Acute Myeloid Leukemia
Hiroto Ishii, Shingo Yano
Cancers (2022) Vol. 14, Iss. 11, pp. 2806-2806
Open Access | Times Cited: 26
Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access
Marcus A. Florez, Jan O. Kemnade, Nan Chen, et al.
Cancer Research Communications (2022) Vol. 2, Iss. 8, pp. 806-813
Open Access | Times Cited: 24
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy
Yiming Gao, Zhibo Zhang, Yao Li, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 22
Association between Mediterranean diet and metabolic health status among adults was not mediated through serum adropin levels
Maryam Shafiei, Donya Poursalehi, Sobhan Mohammadi, et al.
BMC Public Health (2025) Vol. 25, Iss. 1
Open Access
The role of immune dysfunction in obesity-associated cancer risk, progression, and metastasis
Aneesha Kulkarni, Laura W. Bowers
Cellular and Molecular Life Sciences (2021) Vol. 78, Iss. 7, pp. 3423-3442
Open Access | Times Cited: 32
Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases
Yoshiaki Yura, Masakazu Hamada
Cancers (2022) Vol. 14, Iss. 3, pp. 792-792
Open Access | Times Cited: 20
Exosomal LINC00460/miR-503-5p/ANLN positive feedback loop aggravates pancreatic cancer progression through regulating T cell–mediated cytotoxicity and PD-1 checkpoint
Jun Yao, Ruoyu Gao, Minghan Luo, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 20
Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups
Maike Trommer, Anne Adams, Eren Celik, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1240-1240
Open Access | Times Cited: 19
Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
Ester Blanco, Luisa Chocarro, Leticia Fernández, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2676-2676
Open Access | Times Cited: 11
Gut microbial composition associated with risk of premature aging in women with Yin-deficiency constitution
Yingying Zhai, Jing Li, Yanqi Cao, et al.
Frontiers in Cellular and Infection Microbiology (2025) Vol. 14
Open Access
MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
Ravindra Pramod Deshpande, Kerui Wu, Shih-Ying Wu, et al.
EMBO Molecular Medicine (2025)
Open Access
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
Myriam Kossaï, Nina Radosevic‐Robin, Frédérique Penault‐Llorca
ESMO Open (2021) Vol. 6, Iss. 5, pp. 100257-100257
Open Access | Times Cited: 24
Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer
Ramya Ephraim, Jack Feehan, Sarah Fraser, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6131-6131
Open Access | Times Cited: 18
Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer
Yichi Zhang, Yifeng Lin, Daojun Lv, et al.
PeerJ (2022) Vol. 10, pp. e12843-e12843
Open Access | Times Cited: 16
Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
Yuyang Pang, Tingxun Lu, Zijun Y. Xu‐Monette, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5493-5493
Open Access | Times Cited: 9
Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC
Ana Oitabén, Pablo Fonseca, María José Villanueva, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2626-2626
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top